rethinkPeptides Search
Menu
Study breakdown

Your Body's Own Opioids: What We Know and Don't Know About Endogenous Opioid Peptides

ReviewStrong evidence
The takeaway

A comprehensive review reveals that despite decades of research, fundamental questions about how the body's two dozen-plus natural opioid peptides are made, released, and degraded remain unanswered.

24+ natural opioid peptides

Your body produces over two dozen peptides that activate opioid receptors, yet fundamental questions about how they're made and released remain unanswered

What the researchers found

This comprehensive review maps the current understanding of over two dozen endogenous opioid peptides — the body's natural painkillers and reward signals. Key insights include: the synthesis pathways for endomorphins (a class of opioid peptides) remain debated and only recently proposed; opioid peptide release varies dramatically by brain region, with peptides released from specific neural compartments rather than uniformly; the distance peptides diffuse from release sites and how long they last in brain tissue remain poorly understood.

As a translational case study, the review examines how naltrexone (NTX) — the FDA-approved medication for alcohol use disorder — works by blocking the effects of these endogenous peptides. Recent research has clarified which specific opioid peptide activities naltrexone prevents, advancing understanding of why this decades-old drug helps reduce alcohol craving and consumption.

Why it matters

Despite decades of opioid research, fundamental questions about how the body's own opioid peptides work remain unanswered. This review highlights critical gaps — we still don't fully know how endomorphins are made, how far opioid peptides travel in the brain, or exactly which peptide actions drive specific behaviors. Closing these gaps matters enormously because the opioid system is central to pain, depression, and addiction, and better understanding could lead to more targeted treatments with fewer side effects than current approaches.

The numbers in context

Over 24 endogenous opioid peptides reviewed · 4 opioid receptor types (mu, delta, kappa, nociceptin) · Naltrexone FDA-approved since 1984 · Multiple brain circuits examined

How the study worked

This is a narrative review synthesizing published literature on endogenous opioid peptide synthesis, release dynamics, diffusion, degradation, and clinical relevance. The authors reviewed studies spanning molecular biology, neurophysiology, and clinical pharmacology, with a particular focus on recent findings about endomorphin synthesis and naltrexone's mechanism of action in alcohol use disorder.

Who was studied

Review article — no direct study population

What this study cannot tell us

As a narrative review, this paper synthesizes existing knowledge rather than generating new data. The authors acknowledge that many fundamental questions remain open, particularly regarding endomorphin synthesis, peptide diffusion distances, and the precise temporal dynamics of release. The naltrexone discussion focuses specifically on alcohol use disorder and may not fully represent its mechanisms in other conditions.

How to read the evidence

As a review article in Neuropharmacology, this paper synthesizes a broad body of existing research rather than presenting new experimental data. Its strength lies in comprehensively organizing current knowledge and identifying gaps. The evidence it reviews spans from basic molecular studies to clinical trial data on naltrexone.

When this study was published

Published in 2023, this is a recent and up-to-date review that incorporates the latest findings on endogenous opioid peptide biology and naltrexone mechanisms.

The bigger picture

The opioid crisis has intensified interest in understanding the body's natural opioid system. If scientists can better understand how endogenous opioid peptides work — which ones drive reward, which ones manage pain, and how they interact — it could lead to more precise treatments for addiction, chronic pain, and depression that harness or modulate the body's own chemistry rather than relying on synthetic opioids with high abuse potential.

Questions still open

  • Could targeting specific endogenous opioid peptides rather than blocking all opioid receptors lead to addiction treatments with fewer side effects than naltrexone?
  • How are endomorphins actually synthesized in the body — and could this pathway be a drug target?
  • Do individual differences in endogenous opioid peptide levels or diffusion explain why some people are more vulnerable to alcohol use disorder?

Common questions

What are endogenous opioid peptides?
They are natural chemicals your body produces that act on the same receptors as drugs like morphine and heroin. The most well-known are endorphins (the 'runner's high' chemicals), but there are actually over two dozen different opioid peptides. They help regulate pain, mood, stress, reward, and many other functions throughout the brain and body.
How does naltrexone use this knowledge to treat alcohol addiction?
Naltrexone blocks opioid receptors, preventing the body's natural opioid peptides from producing the rewarding feelings associated with drinking alcohol. Recent research has clarified exactly which endogenous opioid activities naltrexone blocks, helping explain why it reduces cravings and drinking in many (though not all) people with alcohol use disorder.

Read the original research

The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder.

Neuropharmacology, 225, 109376

Citation

Margolis, Elyssa B; Moulton, Madelyn G; Lambeth, Philip S; O'Meara, Matthew J. (2023). The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder.. Neuropharmacology, 225, 109376. https://doi.org/10.1016/j.neuropharm.2022.109376